it's a dilution at 20% discount when the price is already down 40% from 9 months ago. so someone is getting a very good deal if things work out... The M&A better pay off or the shareholders are going to be very unhappy at next AGM.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
